AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02791815
Drug: Selexipag
RxNorm normalized name: Selexipag
DrugBank: Selexipag (DB11362)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
Trial: NCT00732121
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg daily for 4 weeks
Trial: NCT01850004
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01245179
Drug: panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week
Trial: NCT00546143
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01903447
Drug: SSRI
RxNorm normalized name: SSRI - Selective serotonin re-uptake inhibitor
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00162136
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
Trial: NCT00233025
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02770391
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
Trial: NCT02770391
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.
Trial: NCT01709318
Drug: Nomegestrol acetate (NOMAC)
RxNorm normalized name: nomegestrol
DrugBank: Nomegestrol (DB11636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily release of 500, 700, or 900 μg.
Trial: NCT01709318
Drug: Etonogestrel (ENG)
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily release of 75, 100, 120 or 125 μg
Trial: NCT01709318
Drug: Ethinyl estradiol (EE)
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily release of 15 μg
Trial: NCT00533949
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22.
Trial: NCT00533949
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22.
Trial: NCT01479036
Drug: docetaxel and epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
Trial: NCT01479036
Drug: docetaxel and epirubicin plus endostatin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
Trial: NCT00461903
Drug: Perindopril
RxNorm normalized name: Perindopril
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
Trial: NCT01903694
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02229097
Drug: Coordinated bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
Trial: NCT00030797
Drug: Irinotecan 70 mg/m2
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
Trial: NCT00030797
Drug: Irinotecan 240 mg/m2
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan i.v. 240 mg/m2 day 1 and day 22
Trial: NCT01816620
Drug: Lenalidomide, Dexamethasone
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle.
Trial: NCT01706952
Drug: Cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
Trial: NCT01706952
Drug: Adrenaline
RxNorm normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
Trial: NCT01316848
Drug: tivozanib
RxNorm normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
Trial: NCT01266772
Drug: Montelukast sodium.
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children with asthma treated with montelukast and budesonide.
Trial: NCT01266772
Drug: Placebo tablet and budesonide
RxNorm normalized name: formoterol and budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Children with asthma treated with placebo tablet and budesonide.
Trial: NCT01323569
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
Trial: NCT01323569
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
Trial: NCT01323569
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
Trial: NCT01323569
Drug: Marinol
RxNorm normalized name: Marinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
Trial: NCT01323569
Drug: Marinol
RxNorm normalized name: Marinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
Trial: NCT04190745
Drug: Toripalimab+Apatinib mesylate
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
Trial: NCT04190745
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 80mg/m2, q3w
Trial: NCT05905185
Drug: Tocotrienol-rich fraction vitamin E (TRF)
RxNorm normalized name: tocotrienols / vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
Trial: NCT01175824
Drug: Insulin Lispro Low Mixture (LM)
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant-dependent dose, administered subcutaneously for 24 weeks
Trial: NCT01175824
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant-dependent dose, administered subcutaneously for 24 weeks
Trial: NCT01175824
Drug: Prandial Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant-dependent dose, administered subcutaneously for 24 weeks
Trial: NCT01010581
Drug: SC12267 (4SC-101)
RxNorm normalized name: SC12267
DrugBank: SC12267 (DB05125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00809289
Drug: esreboxetine
RxNorm normalized name: Esreboxetine
DrugBank: Esreboxetine (DB12395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
Trial: NCT00809289
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
Trial: NCT00111644
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg iv daily
Trial: NCT02030678
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
Trial: NCT03847181
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban at a dose of 15 or 20 mg once daily
Trial: NCT03847181
Drug: Apixaban (Eliquis)
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban at a dose of 2.5 or 5 mg twice daily
Trial: NCT03847181
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin dose as prescribed by medical practitioner
Trial: NCT00699881
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
Trial: NCT01662869
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Trial: NCT01662869
Drug: Onartuzumab
RxNorm normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
Trial: NCT01662869
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Trial: NCT02506114
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01914432
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01914432
Drug: Telmisartan placebo
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01694706
Drug: faldaprevir
RxNorm normalized name: Faldaprevir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium dose of faldaprevir
Trial: NCT01694706
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medium dose of omeprazole
Trial: NCT04734353
Drug: Prasugrel 5mg
RxNorm normalized name: Prasugrel 5mg Oral tablet
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
Trial: NCT04734353
Drug: Ticagrelor 60mg
RxNorm normalized name: TICAGRELOR 60MG TAB
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
Trial: NCT00843791
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
Trial: NCT01324024
Drug: Lisdexamfetamine
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
Trial: NCT01375049
Drug: Aztreonam for Inhalation Solution (AZLI)
RxNorm normalized name: aztreonam Inhalation Solution
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
Trial: NCT01531959
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to blinded to 20 mg of midodrine
Trial: NCT02886585
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04744727
Drug: paracetamol-pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
Trial: NCT02057757
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days.
Trial: NCT00384137
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunosuppression
Trial: NCT00130767
Drug: finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02442921
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: up to 2mg of Colchicine daily
Trial: NCT00650533
Drug: Glimepiride Tablets 1 mg
RxNorm normalized name: glimepiride Oral Tablet
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg, single dose fed
Trial: NCT00633035
Drug: esomeprazole 40 mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg po given for 7 days
Trial: NCT00633035
Drug: famotidine 20 mg
RxNorm normalized name: famotidine 20 MG
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: famotidine 20 mg intravenous bolus q12h for 7 days
Trial: NCT02984995
Drug: Quizartinib
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
Trial: NCT02370888
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
Trial: NCT00621439
Drug: Pegylated Interfon Alpha 2B
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
Trial: NCT02956629
Drug: Uprifosbuvir
RxNorm normalized name: Uprifosbuvir
DrugBank: Uprifosbuvir (DB15206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
Trial: NCT02956629
Drug: Ruzasvir
RxNorm normalized name: Ruzasvir
DrugBank: Ruzasvir (DB11713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
Trial: NCT02956629
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
Trial: NCT01983800
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01983800
Drug: Propofol/midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02202135
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ceftaroline 600mg every 8 hours
Trial: NCT02202135
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV vancomycin 15mg/kg every 12 hours
Trial: NCT02202135
Drug: Aztreonam
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV aztreonam 1 g every 8 hours
Trial: NCT02097875
Drug: BLZ-100
RxNorm normalized name: BLZ-945
DrugBank: BLZ-945 (DB16838)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02461589
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
Trial: NCT02461589
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
Trial: NCT00002912
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002912
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002912
Drug: valspodar
RxNorm normalized name: VALSPODAR
DrugBank: Valspodar (DB11869)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01646034
Drug: chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine
Trial: NCT03755765
Drug: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
RxNorm normalized name: amoxicillin-clavulanate 875 mg-125 mg oral tablet
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Trial: NCT02762669
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin, 10-7mol/L to 10-5mol/L
Trial: NCT02233231
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline 2 mg x 1 day 7 to week 12